CMBA
TVRD

C.M. Bidwell & Associates’s Tvardi Therapeutics TVRD Stock Holding History

C.M. Bidwell & Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-291
Closed -$228K – 631
2021
Q1 		$228K Hold
291
– – 0.17% 113
2020
Q4 		$159K Buy
+291
New +$153K 0.13% 159

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

C.M. Bidwell & Associates's TVRD Position: Q2 2021 in Review

C.M. Bidwell & Associates sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 291 shares — an estimated $228K sold.

C.M. Bidwell & Associates first reported a position in TVRD in Q4 2020 and held it in 2 quarters. The position peaked at $228K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • C.M. Bidwell & Associates reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 291 Tvardi Therapeutics shares in Q2 2021, an estimated $228K.
  • C.M. Bidwell & Associates first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Tvardi Therapeutics position peaked at $228K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2021, filed 13 Aug 2021.